Data as of Apr 17
| +0.06 / +1.72%|
The 5 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 5.00, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a +41.24% increase from the last price of 3.54.
The current consensus among 5 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.